Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease

Justin B. Usery, Timothy H. Self, Muthiah Muthiah, Christopher K. Finch

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation coupled with an abnormal inflammatory process. It is associated with high morbidity and mortality. Leukotriene modifiers, approved by the United States Food and Drug Administration as treatment for asthma and allergic rhinitis, may also alleviate the abnormal inflammatory response seen in patients with COPD. To explore the outcomes of research in this area, we conducted a literature search from 1950-2007, using the PubMed database. We found no published studies that provided conclusive evidence that the available leukotriene modifiers benefit patients with COPD. However, data do suggest that leukotriene modifiers may offer benefits to patients with COPD, including effects that pertain to airflow limitation, neutrophil and lymphocyte chemotaxis, and neutrophil longevity. Added to conventional treatment, these agents appear to reduce symptoms, improve objective measures of disease, and control inflammation. Further studies are needed to determine the precise role of leukotriene modifiers in the treatment of COPD.

Original languageEnglish (US)
Pages (from-to)1183-1187
Number of pages5
JournalPharmacotherapy
Volume28
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Leukotrienes
Chronic Obstructive Pulmonary Disease
Neutrophils
Therapeutics
Chemotaxis
United States Food and Drug Administration
PubMed
Asthma
Outcome Assessment (Health Care)
Databases
Lymphocytes
Inflammation
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease. / Usery, Justin B.; Self, Timothy H.; Muthiah, Muthiah; Finch, Christopher K.

In: Pharmacotherapy, Vol. 28, No. 9, 01.09.2008, p. 1183-1187.

Research output: Contribution to journalReview article

Usery, Justin B. ; Self, Timothy H. ; Muthiah, Muthiah ; Finch, Christopher K. / Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease. In: Pharmacotherapy. 2008 ; Vol. 28, No. 9. pp. 1183-1187.
@article{a4b49c10294b4d2384f6989e6aede718,
title = "Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease",
abstract = "Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation coupled with an abnormal inflammatory process. It is associated with high morbidity and mortality. Leukotriene modifiers, approved by the United States Food and Drug Administration as treatment for asthma and allergic rhinitis, may also alleviate the abnormal inflammatory response seen in patients with COPD. To explore the outcomes of research in this area, we conducted a literature search from 1950-2007, using the PubMed database. We found no published studies that provided conclusive evidence that the available leukotriene modifiers benefit patients with COPD. However, data do suggest that leukotriene modifiers may offer benefits to patients with COPD, including effects that pertain to airflow limitation, neutrophil and lymphocyte chemotaxis, and neutrophil longevity. Added to conventional treatment, these agents appear to reduce symptoms, improve objective measures of disease, and control inflammation. Further studies are needed to determine the precise role of leukotriene modifiers in the treatment of COPD.",
author = "Usery, {Justin B.} and Self, {Timothy H.} and Muthiah Muthiah and Finch, {Christopher K.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1592/phco.28.9.1183",
language = "English (US)",
volume = "28",
pages = "1183--1187",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease

AU - Usery, Justin B.

AU - Self, Timothy H.

AU - Muthiah, Muthiah

AU - Finch, Christopher K.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation coupled with an abnormal inflammatory process. It is associated with high morbidity and mortality. Leukotriene modifiers, approved by the United States Food and Drug Administration as treatment for asthma and allergic rhinitis, may also alleviate the abnormal inflammatory response seen in patients with COPD. To explore the outcomes of research in this area, we conducted a literature search from 1950-2007, using the PubMed database. We found no published studies that provided conclusive evidence that the available leukotriene modifiers benefit patients with COPD. However, data do suggest that leukotriene modifiers may offer benefits to patients with COPD, including effects that pertain to airflow limitation, neutrophil and lymphocyte chemotaxis, and neutrophil longevity. Added to conventional treatment, these agents appear to reduce symptoms, improve objective measures of disease, and control inflammation. Further studies are needed to determine the precise role of leukotriene modifiers in the treatment of COPD.

AB - Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation coupled with an abnormal inflammatory process. It is associated with high morbidity and mortality. Leukotriene modifiers, approved by the United States Food and Drug Administration as treatment for asthma and allergic rhinitis, may also alleviate the abnormal inflammatory response seen in patients with COPD. To explore the outcomes of research in this area, we conducted a literature search from 1950-2007, using the PubMed database. We found no published studies that provided conclusive evidence that the available leukotriene modifiers benefit patients with COPD. However, data do suggest that leukotriene modifiers may offer benefits to patients with COPD, including effects that pertain to airflow limitation, neutrophil and lymphocyte chemotaxis, and neutrophil longevity. Added to conventional treatment, these agents appear to reduce symptoms, improve objective measures of disease, and control inflammation. Further studies are needed to determine the precise role of leukotriene modifiers in the treatment of COPD.

UR - http://www.scopus.com/inward/record.url?scp=51849112807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849112807&partnerID=8YFLogxK

U2 - 10.1592/phco.28.9.1183

DO - 10.1592/phco.28.9.1183

M3 - Review article

C2 - 18752388

AN - SCOPUS:51849112807

VL - 28

SP - 1183

EP - 1187

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -